Phase I/II Trial of Outpatient Docetaxel, Cisplatin, 5-Fluorouracil, Leucovorin (opTPFL) as Induction for Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Authors:
  • CNC. M. Norris
    C. M. Norris
  • RTR. B. Tishler
    R. B. Tishler
  • CLC. C. Lamb
    C. C. Lamb
  • MFM. P. Fried
    M. P. Fried
  • LGL. A. Goguen
    L. A. Goguen
  • HGH. V. Gopal
    H. V. Gopal
  • RCR. Costello
    R. Costello
  • RRR. Read
    R. Read
  • SAS. Adak
    S. Adak
  • MPM. R. Posner
    M. R. Posner

Abstract
The purpose of this study was to establish the maximum tolerated dose (MTD) of docetaxel in an outpatient docetaxel (T), cisplatin (P), 5-fluorouracil (5-FU) (F), and leucovorin (L) (opTPFL) regimen and to obtain preliminary assessment of opTPFL efficacy. Thirty-four patients with stage III or IV squamous cell carcinoma of the head and neck were treated with opTPFL. Docetaxel was escalated from 60 to 95 mg/m2 in combination with 100 mg/m2 cisplatin intravenous bolus, and 2,800 mg/m2 5-FU continuous infusion and 2,000 mg/m2 leucovorin continuous infusion with prophylactic growth factors and antibiotics. Patients who achieved a complete (CR) or partial (PR) response to three cycles received definitive twice-daily radiation therapy. A total of 97 cycles were administered to 34 patients. The major acute toxicities were neutropenia and mucositis. The MTD of docetaxel was 90 mg/m2. Seventy-seven of 97 cycles of were administered on an outpatient basis. The overall clinical response rate to opTPFL was 94%, with 44% CRs and 50% PRs. The MTD of opTPFL is 90 mg/m2 docetaxel. Outpatient administration of opTPFL is tolerable, feasible, and does not alter the ability to administer definitive radiation therapy on schedule.

This publication has 26 references indexed in Scilit: